TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2161302
Drug: Itraconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (100 mg once daily) for 30 days in dermatophytosis
Study: 2161302
Drug: Itraconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (100 mg once daily) for 15 days in pityriasis versicolor
Study: 2161302
Drug: Open phase
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open phase treatment with itraconazole (100 mg once daily) for 15 days
Study: 505491
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (1 gram every 4 hours up to 21 days)
Study: 31400046
Drug: Low-dose meloxicam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose meloxicam (0.025 mg/kg/day PO)
Study: 29211013
Drug: Cenerimod 1
Normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenerimod 1 mg
Study: 29211013
Drug: Cenerimod 0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenerimod 0.5, 1, 2, or 4 mg (once daily for 35 days)
Study: 29211013
Drug: Cenerimod 25
Normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenerimod 25 mg
Study: 29211013
Drug: Cenerimod >1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenerimod >1 mg
Study: 29211013
Drug: Cenerimod ≥10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenerimod ≥10 mg
Study: 25510210
Drug: High-dosage betahistine
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage betahistine (144mg/day)
Study: 23448592
Drug: 10 doses
Normalized name: diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 doses of mupirocin (twice daily for 5 days)
Study: 23448592
Drug: 6 doses
Normalized name: interferon alfa-2b,recomb. 3 million unit/0.2 mL (6 doses per pen = 18 million unit) SUBCUT PEN INJECTOR KIT (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 doses of mupirocin (twice daily for 3 days or thrice daily for 2 days)
Study: 21702402
Drug: Pilocarpine 5
Normalized name: PILOCARPINE 5MG/UNT OPH,CRC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine 5 mg twice daily
Study: 21702402
Drug: Pilocarpine 5
Normalized name: PILOCARPINE 5MG/UNT OPH,CRC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine 5 mg four times daily
Study: 21702402
Drug: Pilocarpine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (both doses)
Study: 19318991
Drug: 14-month treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-month treatment for ADHD
Study: 17520154
Drug: 1% adenosine-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% adenosine-containing dissolvable film, applied twice daily for three weeks
Study: 17520154
Drug: 1% adenosine-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% adenosine-containing dissolvable film, applied twice daily for eight weeks
Study: 12182690
Drug: ER felodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER felodipine 5 mg once daily for 2 weeks
Study: 12182690
Drug: ER felodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER felodipine 10 mg/day for 2 weeks in non-responders
Study: 12182690
Drug: ER felodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER felodipine 5 mg and 10 mg/day
Study: 12182690
Drug: ER felodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER felodipine 5 to 10 mg/day
Study: 9838913
Drug: 30-minute drip
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute drip infusion of granisetron (40 micrograms/kg with 100 ml saline)
Study: 9838913
Drug: 30-second injection
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-second injection of granisetron (40 micrograms/kg with 10 ml saline)
Study: 7528850
Drug: Ajmaline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ajmaline (1 mg/kg as bolus followed by infusion of 15 micrograms/kg/min)
Study: 7528850
Drug: Propafenone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (2 mg/kg, followed by infusion of 30 micrograms/kg/min)
Study: 24024322
Drug: Xiao Pi‐II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiao Pi‐II (100 mL, t.d.s., ante cibum)
Study: 24024322
Drug: Mosapride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride (5 mg, t.d.s., ante cibum)
Study: 16611279
Drug: Tenatoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenatoprazole 40 mg fasting at 7.00 AM
Study: 16611279
Drug: Tenatoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenatoprazole 40 mg fasting at 7.00 PM
Study: 16611279
Drug: Tenatoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenatoprazole 40 mg fed at 9.30 PM
Study: 14523040
Drug: anti-IL-5 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-IL-5 monoclonal antibody (mepolizumab)
Study: 10962766
Drug: 12-session cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-session cognitive behavioral therapy (CBT)
Study: 10962766
Drug: four‐session motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: four‐session motivational enhancement therapy (MET)
Study: 1653883
Drug: Lisinopril (L)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril (L) 10, 20, or 40 mg per day
Study: 1653883
Drug: Captopril (C)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (C) 25, 50, or 100 mg per day
Study: 29767459
Drug: Patiromer 8.4-33.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer 8.4-33.6 g divided twice daily
Study: 27599871
Drug: Sulcardine sulfate
Normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulcardine sulfate 200 mg
Study: 27599871
Drug: Sulcardine sulfate
Normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulcardine sulfate 400 mg
Study: 27599871
Drug: Sulcardine sulfate
Normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulcardine sulfate 800 mg
Study: 27599871
Drug: Sulcardine sulfate
Normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulcardine sulfate 400 mg (fed)
Study: 26181091
Drug: 14 pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 pills of study drug (150 microgram levonorgestrel and 30 microgram ethinyl estradiol combined OCPs)
Study: 24018647
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose management strategy aiming at plasma glucose level of 85 to 110 mg/dL using intravenous insulin
Study: 18937673
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin dosing method (phase B)
Study: 16144800
Drug: BE-8 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BE-8 infusion (anti-IL-6 monoclonal antibody)
Study: 16144800
Drug: Melphalan 220
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 220 mg/m2 plus dexamethasone with BE-8 infusion
Study: 16144800
Drug: Melphalan 200
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 200 mg/m2 and dexamethasone without BE-8 infusion
Study: 12747286
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) treatment combined with folic acid supplementation (1 mg/d)
Study: 12747286
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) treatment combined with placebo
Study: 1991216
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg hydrocortisone
Study: 11053073
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses or long acting triamcinolone
Study: 24469238
Drug: 2-year oral
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-year oral health fluoride varnish-oral health promotion intervention
Study: 22846371
Drug: Nizatidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (300 mg/day) for 4 weeks
Study: 17658395
Drug: Late intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late intensification course (high-dose cytarabine and methotrexate)
Study: 17658395
Drug: Hybrid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid treatment protocol
Study: 10613649
Drug: Recombinant factor
Normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant factor VIII (Recombinate) at a dose of 50 IU/kg
Study: 1375679
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 mg oral dose)
Study: 29171140
Drug: GAD-Alum (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-Alum (20 μg, 2 injections, 30 days apart)
Study: 22834281
Drug: Glutamine (20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (20% solution N(2)‐L‐alanine‐L‐glutamine, 'Dipeptiven' Fresenius Kabi, Germany); 0.4 g/kg/day
Study: 11870934
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 100 mg only (G1)
Study: 11870934
Drug: Heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin infusion followed by 6 months of oral anticoagulation with coumadin (G2)
Study: 10563540
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pantoprazole od
Study: 10563540
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole od
Study: 7569589
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding (started as early as 6 hours postoperatively)
Study: 7569589
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding forbidden until spontaneous restoration of intestinal function
Study: 6377801
Drug: progabide (24.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: progabide (24.3 mg/kg daily for 2 weeks)
Study: 28851055
Drug: Telmisartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (80 mg once per day)
Study: 22149445
Drug: Control (ICP-targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (ICP-targeted therapy without prostacyclin)
Study: 17636186
Drug: Low-intensity VKA
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity VKA treatment (target INR 2.5) plus aspirin (100 mg/day) for the first six months (Group A)
Study: 17636186
Drug: Standard-intensity VKA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-intensity VKA treatment (target INR 3.7) (Group B)
Study: 8678266
Drug: Thiopentone 4‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 4‐6 mg/kg i.v., halothane 0.8‐1.5%, N2O‐‐O2 2:1, no opioids, droperidol 75 micrograms/kg i.v. (Group 1)
Study: 8678266
Drug: Propofol 2‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2‐3 mg/kg i.v., propofol 6‐9 mg/kg.h, alfentanil 30 micrograms/kg.h, N2O‐O2 2:1, no antiemetics (Group 2)
Study: 2354096
Drug: Suxamethonium after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium after sub-paralysing dose of tubocurarine (0.05 mg kg-1)
Study: 2354096
Drug: Suxamethonium after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium after paralysing dose of atracurium (0.5 mg kg-1)
Study: 2354096
Drug: Atracurium (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.5 mg kg-1)
Study: 2354096
Drug: Tubocurarine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubocurarine (0.05 mg kg-1)
Study: 23347435
Drug: Intensive cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive cabergoline treatment (weekly increase by 1 mg per week followed by 4 weekly escalation)
Study: 23347435
Drug: Conventional cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional cabergoline treatment (4 weekly escalation by 0.5 mg per week)
Study: 19210150
Drug: Amlodipine/Olmesartan Medoxomil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/Olmesartan Medoxomil (AML/OM) 10/40 mg
Study: 19210150
Drug: Amlodipine/Valsartan (AML/VAL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/Valsartan (AML/VAL) 10/320 mg
Study: 9215826
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with methotrexate (30 mg/m2 on days 1, 15, and 22), vinblastine (3 mg/m2 on days 2, 15, and 22), doxorubicin (30 mg/m2 on day 2), and cisplatin (70 mg/m2 on day 2)
Study: 9215826
Drug: Single‐agent cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐agent cisplatin (70 mg/m2 on day 1)
Study: 29667217
Drug: False-positive digital
Normalized name: ALLERGENIC EXTRACT, FALSE RAGWEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: False-positive digital rectal exam (DRE)
Study: 25895964
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene and dietary counseling
Study: 25895964
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene and fluoride varnish application at 4, 8, and 12 months
Study: 25895964
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene and tooth mousse applied by parents twice a day for 12 months
Study: 23086138
Drug: TAK-875 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 6.25 mg
Study: 23086138
Drug: TAK-875 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 12.5 mg
Study: 23086138
Drug: TAK-875 25
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 25 mg
Study: 23086138
Drug: TAK-875 50
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 50 mg
Study: 23086138
Drug: TAK-875 200
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 200 mg
Study: 18669462
Drug: Amifostine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (600 mg/m2/dose) administered as a bolus immediately before and 3 hours into the cisplatin infusion
Study: 14607206
Drug: Moxonidine SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine SR (1.5 mg BID)
Study: 8686973
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of lamivudine twice daily plus 200 mg of zidovudine three times daily (low-dose lamivudine group)
Study: 8686973
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of lamivudine twice daily plus 200 mg of zidovudine three times daily (high-dose lamivudine group)
Study: 8686973
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg of zalcitabine plus 200 mg of zidovudine three times daily (zalcitabine group)
Study: 8686973
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of lamivudine plus zidovudine
Study: 8686973
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of lamivudine plus zidovudine
Study: 6337710
Drug: BCNU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCNU plus high-dose methylprednisolone
Study: 29216820
Drug: Sufentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil infusion at 0.2 μg·kg-1·hr-1
Study: 29216820
Drug: Sufentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil infusion at 0.5 μg·kg-1·hr-1
Study: 29216820
Drug: Sufentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil infusion at 0.8 μg·kg-1·hr-1
Study: 29216820
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (0.2, 0.5, 0.8 μg·kg-1·hr-1)
Study: 29216820
Drug: Low-dose infusion
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose infusion of sufentanil
Study: 26719230
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg) added to 500 mg/m² pemetrexed and 75 mg/m² cisplatin (PCB)
Study: 24995954
Drug: Butamirate (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butamirate (various doses)
Study: 18332267
Drug: Vernakalant (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vernakalant (3 mg/kg for 10 minutes, followed by 2 mg/kg 15 minutes later if AF was not terminated)
Study: 16116152
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with stem-cell rescue
Study: 16116152
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (for infants)
Study: 16116152
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy
Study: 7495598
Drug: Self-administered survey
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered survey about risk factors for HIV infection
Study: 2249115
Drug: Oxybutynin hydrochloride
Normalized name: Oxybutynin hydrochloride
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin hydrochloride (3 mg)
Study: 7357798
Drug: Levodopa, 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa, 1,000 mg
Study: 7357798
Drug: Levodopa, 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa, 1,000 mg and Metoclopramide, 10 mg
Study: 20037568
Drug: Carbamazepine (CBM)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBM) 300-1600 mg/day (mean 700±120 mg/day) for 25.43±2.34 months
Study: 20037568
Drug: Oxcarbazepine (OCB)
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine (OCB) 600-1800 mg/day (mean 900±145 mg/day) for 12±0.65 months
Study: 17324224
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg levetiracetam
Study: 17324224
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg levetiracetam
Study: 15505444
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at a target concentration of 3 microg/ml
Study: 9768800
Drug: Propofol plus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol plus alfentanil 50 ng/mL
Study: 9768800
Drug: Propofol plus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol plus alfentanil 100 ng/mL
Study: 21700302
Drug: Standard low-fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard low-fat diet with daily walking (control)
Study: 9083908
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily (days 0-28) plus amoxycillin 500 mg three times daily (days 15-28)
Study: 8472521
Drug: ST-679 (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST-679 (1200 mg single oral dose)
Study: 8472521
Drug: Paracetamol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1000 mg single oral dose)
Study: 3704665
Drug: Myelosuppressive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myelosuppressive agents (32P or chlorambucil) supplemented by phlebotomy
Study: 24045030
Drug: Cocaine, cannabis,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine, cannabis, cigarettes, alcohol use, unintentional overdose, injection drug use
Study: 19083391
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (250 mL daily for 4 weeks)
Study: 19083391
Drug: Apple juice
Normalized name: apple juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple juice (250 mL daily for 4 weeks)
Study: 12614835
Drug: group‐based cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: group‐based cognitive‐behavioral stress management/expressive‐supportive therapy intervention (CBSM+)
Study: 10852273
Drug: Corticosteroid injections
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injections (40 mg of 6‐methylprednisolone acetate)
Study: 27931257
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral health program (without fluoride varnish)
Study: 24666361
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin cream 0.1%
Study: 11732859
Drug: T/T genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: T/T genotype of the 5-HT2A receptor gene
Study: 11732859
Drug: C/C and
Approvals — FDA: no, EMA: no, PMDA: no
Description: C/C and C/T genotypes of the 5-HT2A receptor gene
Study: 2891519
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment (LH‐RH, LH‐RH plus hCG)
Study: 27314247
Drug: Cranberry extract
Normalized name: CRANBERRY EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry extract (PAC‐Aproanthocyanidin‐A), 36 patients, administered for 12 weeks
Study: 27314247
Drug: Placebo, 36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 36 patients, administered for 12 weeks
Study: 18853053
Drug: Prilocaine 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine 3% associated with felypressin 0.03 IU/ml
Study: 16801691
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Air-Stirrup brace, elastic wrap, walking cast)
Study: 12891281
Drug: Atorvastatin (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (combined 10 mg and 40 mg)